Executive Summary
NIH awarded Leidos Biomedical Research $141.7M for a 10-year universal influenza vaccine program, providing Leidos Holdings a stable, low-risk revenue stream through 2031. Only 17% ($24.1M) outlayed signals potential execution delays amid long-term funding risks. Investors should prioritize Leidos for health R&D exposure while monitoring disbursements.
Tracking the trend? Catch up on the prior All HHS Contracts digest from February 03, 2026.
Investment Signals(1)
- Leidos secures $142M long-term NIH flu vaccine contract(HIGH)▲
Cost-plus-fixed-fee delivery order spans to 2031, locking in predictable revenue from health R&D services under full competition.
Risk Flags(1)
- Execution[MEDIUM RISK]▼
Long 10-year period to 2031 exposes to funding cuts or program shifts; only $24.1M (17%) outlayed vs. $141.7M obligated indicates delays.
Opportunities(1)
- ◆
$118M remainder in base + options through 2031; potential for NIH NCI expansions in health R&D competitions.
Sector Themes(1)
- ◆
Massive 10-year commitment to FLUMOSV2 R&D via cost-plus contracts signals sustained federal biotech investment.
Watch List(1)
- 👁
{"entity"=>"Leidos Holdings, Inc.", "reason"=>"Dominates single-record period with $142M locked revenue; partial outlays warrant scrutiny.", "trigger"=>"Outlays exceeding 50% of obligation or new NIH awards"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC